discord retatrutide Retatrutide: Comprehensive Safety and Clinical Data Retatrutide in 2026: Trial Results

Def recommend Frequently asked questions RETA GLP-3 is supplied as a lyophilized (freeze-dried) research peptide in a sealed vial

structural design

Lillys Retatrutide: Toward the End of Incremental Metabolic Medicine Why GLP-1++ therapies are redefining what is worth developing and what is not In early December 2025, Eli Lilly announced landmark Phase 3 results for retatrutide its investigational once-weekly triple hormone receptor agonist targeting GLP-1, GIP, and glucagon

For context, only 4.2% of placebo participants achieved complete pain freedom

The honest answer: Retatrutide looks more powerful on headline weight-loss potential, but there is no true head-to-head trial against CagriSema yet

Respect the four-week cadence